International Flavors & Fragrances (IFF)
NYSEMaterialsSpecialty ChemicalsSnapshot 2026-07-07
$81.81-1.16%
Close 2026-07-07 · 1-day change
Reading IFF? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track IFF free→NYSEMaterialsSpecialty ChemicalsSnapshot 2026-07-07
Reading IFF? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track IFF free→QuarterlyIQ Insights · IFF
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 12 valuation methods, at three horizons. Current price $81.81. As of 2026-07-08. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $82 IFF trades at 19× p/e, below its 23× p/e peer median, but our blended $66 fair value sits below the price. We hold it with medium confidence: our number sits below the analyst range. Analysts target $75–$95. Note: our $66 fair value sits below the entire analyst range ($75–$95). Not investment advice.
$75.00 – $95.00 (median $90.00) · 5 analysts · as of 2026-07-01
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Only weak execution quality — not the full expensive x weak x turbulent stack. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks cheaper than most peers in the same business.
Around its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $90.00 | — | — | Analyst | high |
| dcf fcfe | 12M | $31.54 | — | — | Analyst | high |
| ddm gordon | 12M | $24.89 | — | — | TTM | high |
| graham number | 12M | $72.57 | — | — | TTM | high |
| Peer EV/EBITDA | 12M | $24.65 | 15.2 | 2.98 | TTM | high |
| Peer P/FCF | 12M | $34.88 | 22.5 | 1.55 | TTM | high |
| Peer P/E | 12M | $96.50 | 22.7 | 4.25 | TTM | high |
| Peer P/S | 12M | $60.39 | 1.4 | 41.98 | TTM | high |
| PEG | 12M | $48.92 | 11.5 | 4.25 | TTM | high |
| residual income | 12M | $52.19 | — | — | TTM | high |
| Own P/E history | 12M | $78.71 | 18.5 | 4.25 | TTM | high |
| triangulated | 12M | $98.13 | 22.7 | 4.32 | Triangulated | high |
| Peer P/E | 3Y | $107.24 | 22.7 | 4.72 | Analyst | medium |
| Peer P/S | 3Y | $60.54 | 1.4 | 42.08 | guidance | medium |
| PEG | 3Y | $54.36 | 11.5 | 4.72 | Analyst | medium |
| Own P/E history | 3Y | $87.47 | 18.5 | 4.72 | Analyst | medium |
| Peer P/E | 5Y | $104.52 | 22.7 | 4.60 | Analyst | high |
| Peer P/S | 5Y | $59.00 | 1.4 | 41.01 | guidance | high |
| PEG | 5Y | $52.98 | 11.5 | 4.60 | Analyst | high |
| Own P/E history | 5Y | $85.24 | 18.5 | 4.60 | Analyst | high |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.